Compare Estee Lauder Companies Inc (EL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Zoetis Inc — how do they compare? Estee Lauder Companies Inc trades at $88.23 (market cap $31.76B), while Zoetis Inc trades at $73.52 (market cap $31.14B). The key difference: Estee Lauder Companies Inc and Zoetis Inc are close in size by market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| EL | ZTS | |
|---|---|---|
Market Cap | $31.76B | $31.14B |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $156.76 |
52-Week Low | $67.23 | $71.91 |
Enterprise Value | $37.93B | $38.70B |
Dividend Yield | 1.59% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EL trades at $88.56, up 1.57% today, with a bullish technical trend and strong recent earnings beats. The stock shows robust gross margins of 74.71% but faces profitability challenges with a negative net income margin. Analyst consensus is mixed with a $91.67 price target, while recent news highlights new product launches and institutional accumulation.
Outlook remains cautiously optimistic given earnings momentum and brand strength, but high valuation multiples and inconsistent cash flow pose risks. Investors should weigh growth potential against margin pressures and macroeconomic sensitivity in the beauty sector.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
